Jessica R Allegretti1,2, Edward L Barnes3,4, Betsey Stevens5, Margaret Storm3, Ashwin Ananthakrishnan5,4, Vijay Yajnik5,4, Joshua Korzenik3,4. 1. Division of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02141, USA. jallegretti@bwh.harvard.edu. 2. Harvard Medical School, Boston, MA, USA. jallegretti@bwh.harvard.edu. 3. Division of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02141, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Gastroenterology Unit, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in phase III trials. AIMS: Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. METHODS: Adult patients completing induction therapy with VDZ were eligible for this study. Clinical response and remission was assessed using the Harvey-Bradshaw Index (HBI) for CD, the Simple Clinical Colitis Activity Index for UC and physician assessment. RESULTS: Among 136 total patients (96 CD and 40 UC), 76 (56%) demonstrated clinical response or remission at week 54. In univariate analysis, for patients with CD concomitant initiation of immunomodulator therapy (2.71, 95% CI 1.11-6.57), the addition of an immunomodulator (OR 11.49, 3.16-41.75) and CRP < 3 (4.92, 95% CI 1.99-12.15) was associated with increased odds of clinical response or remission at week 54. For UC patients, hospitalization after VDZ induction was associated with decreased odds of response or remission at week 54 (OR 0.22, 95% CI 0.05-0.88). On multivariate analysis in CD, addition of an immunomodulator (OR 8.33, 95% CI 2.15-32.26) remained significant predictors of clinical response or remission at week 54. CONCLUSIONS: Among a multicenter cohort of patients with IBD demonstrating primary response to VDZ, the addition of combination therapy with an immunomodulator is a significant predictor of clinical response or remission at week 54 in patients with CD.
BACKGROUND:Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in phase III trials. AIMS: Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. METHODS: Adult patients completing induction therapy with VDZ were eligible for this study. Clinical response and remission was assessed using the Harvey-Bradshaw Index (HBI) for CD, the Simple Clinical Colitis Activity Index for UC and physician assessment. RESULTS: Among 136 total patients (96 CD and 40 UC), 76 (56%) demonstrated clinical response or remission at week 54. In univariate analysis, for patients with CD concomitant initiation of immunomodulator therapy (2.71, 95% CI 1.11-6.57), the addition of an immunomodulator (OR 11.49, 3.16-41.75) and CRP < 3 (4.92, 95% CI 1.99-12.15) was associated with increased odds of clinical response or remission at week 54. For UC patients, hospitalization after VDZ induction was associated with decreased odds of response or remission at week 54 (OR 0.22, 95% CI 0.05-0.88). On multivariate analysis in CD, addition of an immunomodulator (OR 8.33, 95% CI 2.15-32.26) remained significant predictors of clinical response or remission at week 54. CONCLUSIONS: Among a multicenter cohort of patients with IBD demonstrating primary response to VDZ, the addition of combination therapy with an immunomodulator is a significant predictor of clinical response or remission at week 54 in patients with CD.
Authors: William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar Journal: Gastroenterology Date: 2011-11-04 Impact factor: 22.682
Authors: Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer Journal: Gastroenterology Date: 2014-05-21 Impact factor: 22.682
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Glen S Hazlewood; Ali Rezaie; Meredith Borman; Remo Panaccione; Subrata Ghosh; Cynthia H Seow; Ellen Kuenzig; George Tomlinson; Corey A Siegel; Gil Y Melmed; Gilaad G Kaplan Journal: Gastroenterology Date: 2014-10-16 Impact factor: 22.682
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Parambir S Dulai; Mahmoud Mosli; Reena Khanna; Barrett G Levesque; William J Sandborn; Brian G Feagan Journal: Pharmacotherapy Date: 2015-04 Impact factor: 4.705
Authors: Parambir S Dulai; Siddharth Singh; Xiaoqian Jiang; Farhad Peerani; Neeraj Narula; Khadija Chaudrey; Diana Whitehead; David Hudesman; Dana Lukin; Arun Swaminath; Eugenia Shmidt; Shuang Wang; Brigid S Boland; John T Chang; Sunanda Kane; Corey A Siegel; Edward V Loftus; William J Sandborn; Bruce E Sands; Jean-Frederic Colombel Journal: Am J Gastroenterol Date: 2016-06-14 Impact factor: 12.045
Authors: Vince B C Biemans; C Janneke van der Woude; Gerard Dijkstra; Andrea E van der Meulen-de Jong; Bas Oldenburg; Nanne K de Boer; Mark Löwenberg; Nidhi Srivastava; Alexander G L Bodelier; Rachel L West; Jeroen M Jansen; Annemarie C de Vries; Jeoffrey J L Haans; Dirk J de Jong; Marie J Pierik; Frank Hoentjen Journal: Clin Pharmacol Ther Date: 2019-12-11 Impact factor: 6.875
Authors: Bharati Kochar; Yue Jiang; Aaron Winn; Edward L Barnes; Christopher F Martin; Millie D Long; Michael D Kappelman Journal: Crohns Colitis 360 Date: 2019-08-29